HLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs

An update from HLS Therapeutics Inc ( (TSE:HLS) ) is now available.

HLS Therapeutics has launched NILEMDO, a once-daily oral non-statin therapy, across Canada for adults who cannot reach LDL-cholesterol targets with current treatments or who are statin intolerant. The drug, in-licensed from Esperion Therapeutics and approved by Health Canada in late 2025, expands HLS’s cardiovascular portfolio alongside Vascepa and is aimed at a sizeable patient population estimated at more than half a million Canadians.

NILEMDO leverages a novel mechanism that lowers LDL-C with a lower likelihood of muscle-related side effects and can be used alone or with statins, ezetimibe, or PCSK9 inhibitors, fitting into existing treatment regimens. Its approval is backed by the large CLEAR Outcomes trial showing significant reductions in major adverse cardiovascular events, while reimbursement submissions are underway with expectations for private coverage this year and potential public reimbursement in 2026, and HLS is also progressing NEXLIZET, a bempedoic acid and ezetimibe combination pill, toward a targeted 2027 Canadian launch.

These developments underscore HLS’s push to become a leader in oral cardiovascular therapies in Canada and may materially improve treatment options and cardiovascular risk management for high-risk patients who have struggled to meet guideline-recommended LDL-C goals. The addition of NILEMDO and the anticipated arrival of NEXLIZET could enhance the company’s competitive standing and broaden access to evidence-backed, non-statin lipid-lowering options for Canadian patients and clinicians.

The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.

Spark’s Take on TSE:HLS Stock

According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.

The score is held back primarily by ongoing net losses and soft revenue trends despite strong gross margins, while positive and improving cash generation and manageable leverage provide support. Technically, indicators point to weak momentum, and valuation remains constrained by negative earnings; the latest earnings call adds a modest positive tilt due to EBITDA growth and debt reduction but is tempered by revenue and product-growth headwinds.

To see Spark’s full report on TSE:HLS stock, click here.

More about HLS Therapeutics Inc

HLS Therapeutics Inc. is a pharmaceutical company focused on treatments for psychiatric disorders and cardiovascular disease, with a strategy of in-licensing and commercializing novel, oral therapies for the Canadian market. Its cardiovascular portfolio, which includes Vascepa and now NILEMDO, targets high-risk patients who are not adequately served by existing standard-of-care options.

By concentrating on unmet medical needs such as statin-intolerant patients or those not reaching LDL-cholesterol targets, HLS aims to strengthen its position as a leading provider of innovative cardiovascular medicines in Canada. The company collaborates with partners like Esperion Therapeutics to bring first-in-class and combination therapies to market, enhancing its competitive profile in specialty pharmaceuticals.

Average Trading Volume: 10,061

Technical Sentiment Signal: Sell

Current Market Cap: C$137.6M

For a thorough assessment of HLS stock, go to TipRanks’ Stock Analysis page.